Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ ... But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold ...

Vertex Pharmaceuticals shares fell 2.5% to close at $469.32 on Friday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Rating page. Readers can sort by stock ticker ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.06% to $460.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28 ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

Vertex Pharmaceuticals reported disappointing Q1 ... I think the biotech stock remains an excellent long-term pick because of the growth prospects for Alyftrek and Journavx as well as the ...